Could this Healthcare Stock really climb 494.50% in 2024?

Earnings Alert. If you cannot see this email properly, please click [here]( --------------------------------------------------------------- Sponsor Message [Limited time left to potentially cash in on AI boom]( There’s a three-step pattern to every tech boom. But the biggest stock market winners don’t often appear until Step Three. So, if you’re worried you missed out on the AI boom, breathe easy. AI just moved from Step One to Step Two. And I think the big money is still ahead There are four stocks I believe will lead to the next wave of the AI boom. [Click here to find out what they are.]( --------------------------------------------------------------- March 11, 2024 (Earnings Report) From the desk of the Editor Dear Reader, We just identified several stocks that are expected to release earnings very soon. If you are interested in any of these companies, we encourage you to do your own research and due diligence before pursuing any investments. Keep in mind, the actual earnings date and time may change, so if you’re interested in any of these companies you will need to pay close attention to their announcements. --------------------------------------------------------------- Sponsor Message [Is Your Money - and Privacy - at Risk?]( digital dollar could be a major threat to both your money and your personal privacy. See how it might impact your financial freedom and data security – and what you can do to protect both. Be informed, stay ahead. [Protect Your Financial Privacy Now]( --------------------------------------------------------------- [Kohl's Corporation]( Symbol: [KSS]( Recent Price: $27.27 Average Analyst Price Target: $26.25 (-3.74%) Market Cap: $3.02B Last Year's EPS: $0.52 Consensus EPS Forecast: $0.35 Expected Earnings Date: Mar 12, 2024 Recent Analyst Action: Dana Telsey, analyst at Telsey Advisory, reiterates coverage on [Kohl's Corporation (KSS)]( in the Consumer Cyclical sector with a Hold rating and a price target of n/a (5 days ago). [TipRanks.com]( also reports that [Kohl's Corporation]( currently has 4 analysts offering 12-month price targets and the consensus is a Hold rating with an average price target is $26.25 . The target pricing ranges from a high forecast of $38 down to a low forecast of $18. [Kohl's Corporation (KSS)](’s last closing price was $27.27 which would put the average price target at -3.74% upside. Here are 3rd party ratings for [KSS](: - TipRanks.com: Hold - TradingView.com: Neutral - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Sell, Top 35% (89 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Rare Chance to Be an Early Investor in AI Energy Breakthrough]( expert Ian King has found a way to invest in the technology powering AI energy. A breakthrough that presents a once-in-a-lifetime opportunity for fast-acting investors. [Just go here for full details.]( --------------------------------------------------------------- [Heron Therapeutics, Inc.]( Symbol: [HRTX]( Recent Price: $2.60 Average Analyst Price Target: $6.38 (145.19%) Market Cap: $390.19M Last Year's EPS: $-0.35 Consensus EPS Forecast: $-0.31 Expected Earnings Date: Mar 12, 2024 Recent Analyst Action: Serge Belanger, analyst at Needham, reiterates coverage on [Heron Therapeutics, Inc. (HRTX)]( in the Healthcare sector with a Buy rating and a price target of $4 (1 month ago). [TipRanks.com]( also reports that [Heron Therapeutics, Inc.]( currently has 4 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $6.38 . The target pricing ranges from a high forecast of $9 down to a low forecast of $10. [Heron Therapeutics, Inc. (HRTX)](’s last closing price was $2.60 which would put the average price target at 145.19% upside. Here are 3rd party ratings for [HRTX](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 35% (88 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [[BREAKING] Small Firm Wins $1 Billion Army Contract for Breakthrough "Living Software"]( The Washington Post Reports it's: "A revolution in warfare." The Sunday Times Reports it's: "a revolutionary power." Early investors can reap 5,633% gains as England, Germany, Japan and Australia rush to sign contracts. [Get the name of the stock here ]( --------------------------------------------------------------- [Core Scientific, Inc.]( Symbol: [CORZ]( Recent Price: $4.03 Average Analyst Price Target: $8.50 (110.92%) Market Cap: $0.00 Last Year's EPS: $-2.65 Consensus EPS Forecast: $-0.17 Expected Earnings Date: Mar 12, 2024 Recent Analyst Action: Chase White, analyst at Compass Point, reiterates coverage on [Core Scientific, Inc. (CORZ)]( in the Technology sector with a Buy rating and a price target of $8.5 (1 month ago). [TipRanks.com]( also reports that [Core Scientific, Inc.]( currently has 1 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $8.50 . The target pricing ranges from a high forecast of $8.5 down to a low forecast of $8.5. [Core Scientific, Inc. (CORZ)](’s last closing price was $4.03 which would put the average price target at 110.92% upside. Here are 3rd party ratings for [CORZ](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: n/a - Zacks.com: Hold, Bottom 43% (143 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- [Clearside Biomedical, Inc.]( Symbol: [CLSD]( Recent Price: $1.67 Average Analyst Price Target: $5.20 (211.38%) Market Cap: $124.78M Last Year's EPS: $-0.15 Consensus EPS Forecast: $-0.16 Expected Earnings Date: Mar 12, 2024 Recent Analyst Action: Jonathan Wolleben, analyst at JMP Securities, reiterates coverage on [Clearside Biomedical, Inc. (CLSD)]( in the Healthcare sector with a Buy rating and a price target of $5 (1 month ago). [TipRanks.com]( also reports that [Clearside Biomedical, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $5.20 . The target pricing ranges from a high forecast of $6 down to a low forecast of $4. [Clearside Biomedical, Inc. (CLSD)](’s last closing price was $1.67 which would put the average price target at 211.38% upside. Here are 3rd party ratings for [CLSD](: - TipRanks.com: Buy - TradingView.com: Buy - Yahoo! Finance: Bullish Short-Term Outlook - Barchart.com: Strong buy - Zacks.com: Hold, Top 31% (79 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [My Gift to You]( I have arranged for you to receive [a complimentary 3-month subscription]( to Bernie Schaeffer’s Option Advisor online newsletter. [CLICK HERE]( for 3 Months FREE of Bernie Schaeffer’s Option Advisor ($395 Retail Value - [FREE!]() --------------------------------------------------------------- [Precision BioSciences, Inc.]( Symbol: [DTIL]( Recent Price: $12.01 Average Analyst Price Target: $71.40 (494.50%) Market Cap: $78.83M Last Year's EPS: $-3 Consensus EPS Forecast: $-5.71 Expected Earnings Date: Mar 12, 2024 Recent Analyst Action: Patrick Trucchio, analyst at H.C. Wainwright, reiterates coverage on [Precision BioSciences, Inc. (DTIL)]( in the Healthcare sector with a Buy rating and a price target of $90 (3 weeks ago). [TipRanks.com]( also reports that [Precision BioSciences, Inc.]( currently has 5 analysts offering 12-month price targets and the consensus is a Buy rating with an average price target is $71.40 . The target pricing ranges from a high forecast of $90 down to a low forecast of $42. [Precision BioSciences, Inc. (DTIL)](’s last closing price was $12.01 which would put the average price target at 494.50% upside. Here are 3rd party ratings for [DTIL](: - TipRanks.com: Buy - TradingView.com: Sell - Yahoo! Finance: Bearish Short-Term Outlook - Barchart.com: Weak sell - Zacks.com: Hold, Top 31% (79 out of 252) [Click for chart >>]( -------------------------------------------------------------------------- --------------------------------------------------------------- Sponsor Message [Richest investors clearly worried about something big]( Dalio, John Paulson, and many others all recommend you own gold right now. But did you know there's another huge investor (worth more than all the world's billionaires COMBINED) buying gold by the ton? That's why the best move to make right now could be this little-known gold investment (which you can get started with for just $5.) [Click for full story.]( --------------------------------------------------------------- And there you have it--- Stocks expected to release earnings soon... Sincerely, The Editor, MarketInsidersPress.com MarketInsidersPress.com Disclaimer This newsletter contains advertisements which are neither an offer nor recommendation to buy or sell any security. Content marked as "Ad," "Special" or "Sponsor" may be a third party advertisements where the advertiser is paying per click, per lead or per sale and are not endorsed or warranted by our staff or company. Sandpiper Marketing Group, LLC is also being compensated by Summit Publishing Group and Investing Trends up to three dollars per click and may exceed twelve thousand, five hundred dollars per week for placement of specific advertisements contained in this newsletter. Sandpiper Marketing Group, LLC and its principles do not own any of the stocks mentioned in this email or in the article that this email links to. Please see the disclaimer on the advertiser's website for additional information, including their relationship with any mentioned security. Compensation for advertising constitutes a conflict of interest as to our ability to remain objective in our communication regarding any companies profiled. Because of this conflict, individuals are strongly encouraged to not use this newsletter as the basis for any investment decision. This newsletter may contain information regarding investment ideas and third-party ratings regarding specific securities. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. Sandpiper Marketing Group, LLC nor its principals are FINRA-registered broker-dealers or investment advisers. The content of this email should not be taken as advice, an endorsement, or a recommendation from Sandpiper Marketing Group, LLC to buy or sell any security. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment. The content in this newsletter or email is not provided to any individual with a view toward their individual circumstances. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between the any predictions and actual results. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. [If you are not a human, click here.]( By opening this email or clicking any links contained, you are reconfirming your opt-in status. You can unsubscribe at any time by clicking the link below in the footer. This is part of your free subscription to MarketInsidersPress.com MarketInsidersPress.com part of Sandpiper Marketing Group, LLC 165 Lockerbie Lane | Mooresville NC | 28115 MarketInsidersPress.com part of Sandpiper Marketing Group, LLC | 1519 Mecklenburg Hwy | Unit 4 | Mount Mourne | NC | 28123 | United States | 877-411-9808 [Unsubscribe]( | [Report spam]( Sent with [ActiveTrail]( software